cyrilzakka/clinical-trials huggingface dataset:
A Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults

The enrolled subjects will get an intravenous cannulation in both elbows. The subject will get before xylocaine spray is placed, the intervention-arm, one intravenous cannulation in one of the elbows, the other intravenous cannulation is placed in the other arm before placebo spray is placed, the control arm. The pain score during insertion of the cannulation, the incidence of adverse events and the success rate and degree of difficulty to place an intravenous cannulation. The subjects and the one who place the cannulations will be blinded to the treatment.

The enrolled subjects will get an intravenous cannulation in both elbows. The influence of the left or right-handedness is reduced by randomizing the arms of the subjects in the placebo group or xylocaine group. The subject will get before xylocaine spray is placed, the intervention-arm, one intravenous cannulation in one of the elbows, the other intravenous cannulation is placed in the other arm before placebo spray is placed, the control arm. The pain score during insertion of the cannulation, the incidence of adverse events and the success rate and degree of difficulty to place an intravenous cannulation. The subjects and the one who place the cannulations will be blinded to the treatment.

Eligibility Criteria:
Inclusion Criteria:

* Adults (aged 18 or older)
* Signing of the informed consent paper

Exclusion Criteria:

* Allergy for xylocaine
* Pregnancy or breast-feeding
* Peripheral neuropathy
* Analgesics in the last 24 hours
* Skin conditions (eczema, psoriasis, infection, or abrasions)
* Difficulties in verbal communication
* No intravenous access in both elbows possible (eg status after axillary dissection )
Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy

This is a prospective examination of ribonucleic acid (RNA) extracted from tumor material of breast cancer patients treated with a neo-adjuvant therapy. The RNA will be analysed for expression of estrogen receptor (ER 1), progesterone receptor (PgR), HER2 and Ki-67 with MammaTyper™.

According to the determined values for the individual parameters at least 4 subtypes can be distinguished to date

* Luminal A-type
* Luminal B-type
* HER2-type
* Triple-negative-type As non-clinical endpoint, the agreement of new subtyping with Immunohistochemical methods will be evaluated.

As clinical objective, the 5 year Distant metastasis free survival (DMFS) and Overall survival (OS) will be reevaluated according to the new subtyping.

Tumor material collected from patients who received neoadjuvant therapy either with four cycles of doxorubicin 60 mg/m² plus pemetrexed 500 mg/m² on day 1 every 21 days followed by four cycles of docetaxel 100 mg/m² on day 1 every 21 days or four cycles of doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² on day 1 every 21 days followed by four cycles of docetaxel 100 mg/m² on day 1 every 21 days will be re-analyzed with the MammaTyper Kit. The Kit is an in-vitro molecular diagnostic test for molecular subtyping of breast cancers into Luminal A \& B, HER2 and Triple negative. It allows quantitative detection of the RNA expression status of the genes for estrogen receptor (ESR1), PgR, HER2 and Ki-67 on the basis of their mRNA present in the samples. This prospective diagnostic study will investigate the subtyping-results of the MammaTyper™ analysis and will compare them to the subtyping of the former immunohistochemical analysis performed. Based on the MammaTyper™-subtypes the efficiency of the therapy regimen and the outcome will be re-evaluated from the patient data.

Eligibility Criteria:
Inclusion Criteria:

* Women aged 18-70 years with histologically confirmed primary invasive breast cancer stages T2-T4/N0-N2/M0 with a tumor size of ≥ 2 cm as measured by ultrasound
* The patient provides a written informed consent for analysis of tumor material

Exclusion Criteria:

* Prior anticancer therapy with an anthracycline or other prior antitumor therapy for breast cancer
* Inflammatory or exulcerating breast cancer
* A second primary malignancy \[except carcinoma in situ (CIS) of the cervix or adequately treated nonmelanoma skin cancer\] unless diagnosed and treated ≥ 5 years ago with no evidence of recurrence
* Any serious concomitant systemic disorder
Registry Study on Respiratory Monogenic Diseases in Chinese Children

This study is a multicenter, prospective cohort study of patients diagnosed with respiratory monogenic diseases, the clinical information of recruited patients, including clinical manifestations, lung function, chest imaging, quality of life and other indicators, will be followed for 5 years.

All new cases of respiratory monogenic diseases was confirmed or diagnosed at each center from the beginning of the study are made the investigation of the clinical manifestations and specific tests by the standard diagnostic process.Then all the patients' following clinical data will be followed for 5 years: clinical manifestations, lung function, chest imaging (once per year), gene test, quality of life and other indicators.

Eligibility Criteria:
Inclusion Criteria:

1. Age: 0-18 years, male and female.
2. Any organ system symptoms consistent with the diagnostic points of respiratory monogenic diseases.
3. Agree to retain specimens related to disease research and agree to store the specimens in the sample bank.
4. willing and able to cooperate with long-term follow-up.
5. The guardian of the child has a full understanding of the purpose of the study, a basic understanding of the clinical research program, and voluntarily allows the child to participate in the study and sign an informed consent form.

Exclusion Criteria:

1. It is unable to provide complete medical records or the current condition can not accept the diagnosis process
2. She or he cannot agree to participate in the study.
Cut-off Values of Muscle Thickness Ratio for Sarcopenia

The loss of muscle mass is one of the major diagnostic criteria for sarcopenia. Many methods are also used for the definition of sarcopenia. However there is no information about cut-off values in this respect in the literature. Therefore, the aim of this study is to determine the cut-off values of this ratio for confirming the diagnosis of sarcopenia.

Decreases in total skeletal muscle mass are accepted to be necessary for confirming the diagnosis of sarcopenia. Many methods are also used for the definition of sarcopenia.

However, ultrasound measurements has a high sensitivity and specify for confirming the diagnosis of sarcopenia. However there is no information about cut-off values in this respect in the literature. Therefore, the aim of this study is to determine the cut-off values of this ratio for confirming the diagnosis of sarcopenia.

Eligibility Criteria:
Inclusion Criteria:

* To be a volunteer to participate
* To be an aged 18-90 years old.

Exclusion Criteria:

* Walking with assist device
* Having a visual deficits
* Having an undergone orthopedic surgery
* Having a cardiac pacemaker
* Having a hypothyroidism, diabetes mellitus, renal/hepatic failure
Canadian Critical Care Comparative Effectiveness Platform

The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.

Many supportive therapies used daily in the ICU setting remain under-studied despite being resource-intensive. CEPEC aims to incorporate domains evaluating vasopressors, platelets, nutrition, sedation and analgesia, and other interventions.

The first domain studied will be vasopressors. The investigators will investigate whether vasoactive medications should be used differently for different subgroups of patients who are in a state of cardiovascular shock (i.e. heterogeneity of treatment effects). Vasoactive medications are common in critically ill patients, and have considerable patient, hospital, and health system resource impact, but their use remains poorly supported by scientific evidence.

Eligibility Criteria:
CEPEC PLATFORM Inclusion Criteria:

* Admitted to a participating intensive care unit (ICU).

CEPEC PLATFORM Exclusion Criteria:

* Goals of care are strictly palliative or expected to become strictly palliative within 24 hours
* Death predicted by the treating team to occur within 24 hours.

To be included in any of the following DOMAINS the participant must met eligibility for the PLATFORM (as listed above).

VASOPRESSORS DOMAIN

Inclusion Criteria:

1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;
2. Mean arterial pressure (MAP) less than 75 mmHg at any point (or lower than the upper value of the highest MAP target range activated locally);
3. Patient expected to be in the ICU for more than 48 hours.

Exclusion Criteria:

1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;
2. Acute traumatic brain injury (within 7 days days or ongoing active treatment for elevated intracranial pressure);
3. Acute subarachnoid hemorrhage (within 21 days);
4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);
5. Lung, heart, liver, kidney transplant recipient (within 7 days);
6. More than 24 hours since meeting inclusion criteria in the ICU;
7. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.
Hemodynamic and Inflammatory Responses in Thoracic Surgery

Video-assisted thoracoscopic surgery (VATS) for thoracic surgery is practical, has been shown to reduce postoperative discomfort, and has improved cosmetic results when compare to open thoracotomy. The specific aims of this project are: to clarify the physiologic and immunologic effects of different approaches for minimally invasive thoracic surgery: (1) multiple-port VATS; (2) single-port VATS

Video-assisted thoracoscopic surgery (VATS) was first reported in the early 1990s. Since then, the safety and efficacy of thoracoscopy for diagnosing and treating pleural, pulmonary, and mediastinal disease has been demonstrated with similar oncological results, which were confirmed by multiple clinical studies. Although VATS for thoracic surgery is practical, has been shown to reduce postoperative discomfort, and has improved cosmetic results when compare to open thoracotomy, unfortunately chronic thoracic wound discomfort and postoperative neuralgia were found in a significant portion of patients .

Recently, a minimally invasive approach that is different from the conventional multiport thoracoscopic technique is gradually becoming of great interest in the diagnosis and treatment of thoracic surgical disease. Single-port VATS is one of the most promising emerging surgical techniques which allows the surgeon to perform a majority of thoracic surgeries and with similar perioperative outcomes that are comparable with the conventional multiport technique. However, a very limited number of clinical studies have demonstrated the advantages of single port VATS in postoperative pain reduction, when comparing to the traditional multiport thoracoscopic approach.

To clarify the physiologic and immunologic effects of different approaches for minimally invasive thoracic surgery, investigators aim to compare the perioperative physiological changes, immunological responses, and postoperative pain between standard (multi-port) transthoracic thoracoscopic and single-port transthoracic thoracoscopic surgery for thoracic disease.

Eligibility Criteria:
Inclusion Criteria:

* Patient with thoracic surgical diseases(lung cancer. mediastinal tumor. solitary pulmonary lesion. pneumothorax) who will be underwent video-assisted thoracic surgery

Exclusion Criteria:

* Unresectable mediastinal tumor
* Previous history of ipsilateral pulmonary resection
* Patients with complex cardiopulmonary dysfunction
* Unresectable pulmonary hilar tumor
Ultrasound Acute Chest Syndrome Sickle Cell Disease

Feasibility and reliability of ultrasound in the inpatient hematology setting.

Acute chest syndrome (ACS) is a complication of sickle cell disease where individuals have symptoms of fever, low oxygen levels or difficulty breathing in the setting of a new lung finding on chest x-ray. Chest x-ray is a useful tool to identify it but has some side effects. The investigators think ultrasound will be an equally feasible, reliable tool and minimize some of the side effects associated with chest x-ray. Ultrasound is a non-invasive was to obtain an image that does not require radiation.

Eligibility Criteria:
Inclusion Criteria:

1. Age: 0-25 years old
2. Diagnosis: Patients with a documented diagnosis of sickle cell disease (any genotype)
3. Disposition: Hospitalized for a SCD-related complication (e.g. VOC)

Exclusion Criteria:

1. Patient is considered hemodynamically unstable to undergo consent and study procedures
2. Already has diagnosis of ACS prior to admission to inpatient unit
3. POCUS operator not available
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, inflammatory, neurodegenerative, and autoimmune disease that progresses with progressive neurological dysfunction and affects the central nervous system. A multidisciplinary rehabilitation approach is crucial in the systematic and supportive treatment of MS. Exercise training is a therapeutic approach that minimizes functional capacity loss and slows progression in MS. Randomized controlled studies have shown that exercise training improves physical fitness, reduces motor fatigue, and improves the quality of life and psychological state in individuals with MS.

When the literature is examined, it is seen that popular exercises such as pilates, yoga, and Tai-Chi are used in addition to aerobics, strengthening, endurance, and stretching exercises in the treatment of individuals with MS. In order to eliminate the economic burden, which is one of the exercise barriers of individuals, and to gain exercise habits, home exercise programs should be expanded. When the literature is examined, it is emphasized that the importance of home exercise programs is emphasized, and it is very important in the treatment of patients who cannot attend an exercise program, especially by going to any center for various reasons. However, there is little information on the effectiveness and content of home exercise programs in patients with MS. From this point of view, this study is capable of supporting the missing part of the literature.


Eligibility Criteria:
Inclusion Criteria:

1. To be between the ages of 18-65
2. Being diagnosed with MS according to McDonald criteria
3. Having an EDSS score between 0-5.5
4. Being in the Relapsing Remitting class as a clinical subtype of MS
5. Not having any nervous system pathology other than MS
6. Not having an MS attack in the last 1 month
7. To ensure full cooperation and adaptation throughout the study.

Exclusion Criteria:

1. Being in an exacerbation period
2. To have participated in a regular physical activity program in the last 6 months
3. Having an orthopedic, cardiopulmonary or psychiatric disease that prevents exercise
4. Continuing another exercise therapy
5. Not volunteering to participate in the study
6. Having problems with reading comprehension
Red Light Photobiomodulation and Topical Disinfectants

The goal of this clinical trial is to evaluate the potential effects of photobiomodulation when used with topical disinfectants in the anterior nares of healthy adults.

Over a three week period, participants will have their anterior nares swabbed with methylene blue, chlorhexidine gluconate, or a combination of the two followed by 4 minutes of non-thermal red light treatment. The fourth week of consist of only red light treatment. Culture samples of the subjects nasal microbiome will be taken prior to treatment, immediately after treatment, 4-, 8-, 24-, and 48 hours after treatment.

This is an exploratory, single-center, open-label, single-arm study with microbiological endpoint using photobiomodulation (PBM) and topical disinfectants to determine the effect on the nasal microbiota.

The photobiomodulation system distributes about 700mW of light to each nostril using a 2-channel diode laser with non-thermal, red light. The topical disinfectants are methylene blue (0.01%) and chlorhexidine gluconate (0.25%). Following a pretreatment nasal culture, these two disinfectants will be administered into the patient's anterior nares followed by a two-minute light cycle. This process is repeated once more resulting in two treatments cycles (4-minutes total). Following this, nasal cultures are taken immediately and at 4-, 8-, 24-, and 48- hours. Broad spectrum and Staphylococcus spp. culturing of nasal swabs will be conducted. Swabs will also be submitted for Next Generation Sequencing to characterize the effect of light and disinfectants on the nasal microbiome.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must be 18 years of age or older

Exclusion Criteria:

* Pregnant Women
* Those Under 18 years of age
* Prisoners
* Mentally Disabled Persons
Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS)

STRATUS will evaluate the use of small-volume ("soft-draw") blood collection tubes for laboratory testing in reducing anemia and transfusion in intensive care unit patients without significant adverse consequences. This is a simple, cost-neutral intervention that could improve the quality of patient care and reduce the harms of frequent laboratory testing.

The STRATUS Pilot Study is a prospective observational study (before-after design) to assess the feasibility of implementing a full-scale randomized trial powered for clinical outcomes (RBC transfusion, incidence and severity of anemia). Identification of barriers and facilitators of implementation will enhance the conduct of the full-scale trial and facilitate incorporation of the intervention into routine practice.

Eligibility Criteria:
Investigative Site Eligibility:

* Intensive care unit with at least 15 beds with capacity for mechanical ventilation
* Current standard to use standard-draw blood collection tubes
* Availability of hospital administrative data and electronic patient information
Data Collection Atrial Fibrillation Exploratory Study

To characterize the impact of Atrial fibrillation (AFib) and Atrial Flutter (AFl) on signals measured using a wearable cardiac monitor prototype device.

To evaluate the relationship of AFib/AFl symptom severity with various physiologic signals measured from the wearable cardiac monitor prototype device.

The is a non-randomized feasibility study that will enroll up to 50 participants with an ongoing episode of AFib/AFl and are referred for a cardiac ablation or electrical cardioversion procedure. A maximum of 20 persistent AFib, 20 paroxysmal AFib, and 20 AFl participants will be enrolled, not to exceed 50 total. There will be up to three data collection visits.

Visit 1 will occur on the same day as enrollment and prior to the cardiac ablation or electrical cardioversion procedure. This allows collection of physiologic signals while the patient is in AFib or AFI.

Visit 2 will occur after the cardiac ablation or electrical cardioversion procedure; no earlier than the day after the cardiac ablation or electrical cardioversion procedure and no more than 4 months after the day of the procedure.

Visit 3 is optional, and may be scheduled upon sponsor's request, which will take place at least 5 months after the previous (second) data collection visit.

Eligibility Criteria:
Inclusion Criteria:

* Able to understand and willing to provide written informed consent to participate in the trial
* Age 18 years old or greater
* Willing and able to participate in study visits and the required testing
* Diagnosed with paroxysmal AFib or persistent AFib or AFl and scheduled for a cardiac ablation or electrical cardioversion procedure
* Confirmed AFib/AFl at the time of enrollment

Exclusion Criteria:

* Currently enrolled in another clinical trial that may interfere with the placement of study system or include the usage of unapproved drugs
* Participant is pregnant or planning to become pregnant during the study
* Diagnosed with permanent AFib
* Active Implantable Medical Device, e.g. cardiac implantable electronic devices, bladder stimulators, diaphragm stimulators, implantable neuro stimulator, implantable active monitoring devices, implantable active drug administration devices, etc.
* Known allergy to materials used in the study (adhesive tape, ECG electrodes)
* Have a prosthetic cardiac valve or previously underwent cardiac valve surgery.
The Financial Navigator Program

Over one third of caregivers with a child admitted to the Hospital for Sick Children (SickKids) reported having difficulty making ends meet. The SickKids Medical-Financial Partnership (MFP) working group conducted in-depth interviews exploring financial needs and supports with selected caregivers in the Neonatal Neurodevelopmental Follow-up Program (NNFU). Results identified financial stress (including difficulties with employment, high cost of living, poverty, food insecurity, inaccessible supports, benefit time lines, costs of therapy) as a major theme. Caregivers generally supported the idea of hospital-based financial services. In this feasibility study we will trial a Financial Navigator Program in the NNFU.

The objective of the current proposal will be to evaluate the feasibility of the Financial Navigator Program in the NNFU.

Research question: What is the feasibility of a Financial Navigator Program in the NNFU?

Setting: The NNFU program follows infants who had a Neonatal Intensive Care admission. Follow-up appointments are scheduled for when the infant is 4, 8, 12, 18 and 36 months of age. We will invite all families at their first appointment in the NNFU to participate in our study.

Study Procedure: Caregivers will be informed about the study at their child's first NNFU visit at 4 months. The clinical team will introduce the study and if interested, they will be approached by a Research Assistant (RA) to provide more details of the study. This can be in person at the clinic visit or in a follow-up phone call depended on families preference. If the caregiver provides consent, an appointment with the Financial Navigator will be arranged.

Intervention: "Access to a Financial Navigator" We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed.

Eligibility Criteria:
Inclusion Criteria:

* Caregivers with a child followed in the NNFU in SickKids will be invited to participate in our study.
* Caregiver needs to attend 4-month NNFU appointment.

Exclusion Criteria:

* There are no exclusion criteria.